Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

(TM), a late-stage vaccine candidate for the treatment of advanced prostate cancer, was acquired as part of the partnership that was entered with the National Cancer Institute. Very promising data were reported, showing prolonged survival combined with a favourable safety profile. Phase III studies expected to be initiated in 2010. - MVA-BN(R) Anthrax, a new preclinical programme for an anthrax vaccine, is expected to enter clinical trials in 2010. - MVA-BN(R) HIV multiantigen, in development as prophylactic and therapeutic vaccine against HIV, initiated clinical Phase I/II trials. - The company's MVA-BN(R) based prostate cancer vaccine also entered clinical Phase I/II trials. - A milestone payment of USD 25 million was received after submission of important IMVAMUNE(R) data. - The data that were generated from a larger Phase II study with IMVAMUNE(R) was submitted to the US health authorities for evaluation whether they can potentially support the use of IMVAMUNE(R) in a declared emergency. - More than 2,400 subjects have now been vaccinated with IMVAMUNE(R) - The first IMVAMUNE(R) contracts outside USA were signed with Canada and an Asian country.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "2008 was a successful year for Bavarian Nordic where all our primary goals were achieved. We implemented a new strategy, and this has already borne fruit. Our increased focus on cancer therapies which through to the partnership with the NCI led to the acquisition of PROSTVAC(TM) has strengthened our pipeline and we feel very optimistic about our cancer vaccines in the future. At the end of the year, we submitted the important safety data for IMVAMUNE(R) to the US health authorities and are now awaiting just one approval in order to initiate the delivery of the 20 million doses under the RFP-3
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... ... weighing needs and expertly narrows down the product choices to a manageable shortlist ... pares down the list to models that fit best with the customer’s industry ...
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... pre-clinical activities with respect to our Oral Amp ... a contract manufacturer," said Andrew Rae , ...
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... note: , ,As promised, our latest e-mail newsletter contains the ... has increased from around 30,000 visitors a month to over ... than a few stories weve paid attention to what drew ... who has already registered for Fusion2006. The conference isnt until March ...
... Corporation for Assigned Names and Numbers, is all about a ... golden key is a name on the net called a ... key management system so that billions of single domain name ... problem. After all, without this access, the Internet has no ...
... researchers led by stem-cell pioneer James Thomson have ... and better-defined lab conditions than previous cultures. , ... could pave the way for stem-cell treatments with ... contamination. Growing stem cells in the lab requires ...
Cached Biology Technology:When will the Internet be divided among nations? 2When will the Internet be divided among nations? 3When will the Internet be divided among nations? 4When will the Internet be divided among nations? 5
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... the most of the spectacular traits in nature: the wild ... walruses and antlers on moose. Sexual conflict the battle ... be a particularly potent force in driving the evolution traits ... processes responsible for producing such traits are not well understood, ...
... of brain activity in the rat brain that play ... and decision-making. The discovery, which builds on the team,s ... and post-traumatic stress syndrome. The researchers previously identified ... brain region critical for memory storage. The patterns sometimes ...
... essential for making informed choices, suggests a study in ... scientists funded by the National Institutes of Health. The ... by selectively suppressing replay encoded as split-second bursts ... performing a maze task., "It appears to ...
Cached Biology News:Biologists turn back the clock to understand evolution of sex differences 2Rats recall past to make daily decisions 2Rats recall past to make daily decisions 3Awake mental replay of past experiences critical for learning 2Awake mental replay of past experiences critical for learning 3